Abbott Laboratories Corporation

Abbvie Inc.

Other

Walter and Eliza Hall Institute of Medical Research

William J McClellan

Aaron R Kunzer

Milan Bruncko

Hong Ding

Xilu Wang

Michael D Wendt

Steven Elmore

Andrew M Petros

Xiaohong Song

Cheol-Min Park

Christopher L Lynch

Le Wang

Lisa A Hasvold

Gerard M Sullivan

Noah Tu

Robert A Mantei

Andrew J Souers

Zhi-Fu Tao

Wang Shen

Dachun Liu

Saul H Rosenberg

Keith F McDaniel

Laura A Hexamer

Yujia Dai

George A Doherty

Gary T Wang

David John Augeri

Todd Warren Rockway

George S Sheppard

James H Holms

Alexander R Shoemaker

Chang H Park

Steven D Fidanze

Michael J Mitten

Thorsten K Oost

John K Pratt

Stephen W Fesik

Daniel A Dickman

Sheela A Thomas

Jurgen Dinges

Philip J Hajduk

Xiahong Song

Cheol Min Park

Steven A Baumeister

David S Garvey

John F DeBernardis

Todd M Hansen

Kent D Stewart

Anthony K Fung

Stephen J O'Connor

William R Baker

Daniel Joseph Kerkman

Herman H Stein

Carol K Wada

Moshe Weitzberg

Stephen A Fakhoury

Rajnandan N Prasad

David G Nettesheim

Jasmina Marjanovic

Andrew G Geyer

Warren M Kati

Robert E Zelle

Robin R Frey

David M Stout

Ramzi Farah Sweis

David L Arendsen

Noel S Wilson

Justin D Dietrich

Guillaume Laurent Lessene

Peter Edward Czabotar

B Gregory Donner

David D Nettesheim

Mike Michaelides

Steven W Elmore

Peter Malcom Colman

The present invention provides for compounds of formula (I). wherein R, R, R, L, G, A, A, A, and Ahave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I). 

Bromodomain inhibitors

The present invention provides for compounds of formula (I) wherein R, X, Y, Y, L, A, A, A, A, A, A, A, and A, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I). 

Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided. 

The invention provides for compounds of formula (I) wherein R, R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Substituted indoles

The present invention provides for compounds of formula (I) wherein R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Dihydro-pyrrolopyridinone inhibitors

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

The present invention provides for compounds of formula (I) wherein A, A, A, A, X, X, Y, L, G, R, and Rhave any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

Apoptosis promoters

Growing community of inventors

Waukegan, IL, United States of America

William J McClellan